The Society aims to plan collaborative projects requiring larger numbers than possible at one centre. Individuals may also seek to involve other
News & Social Feeds
News and Information from the British Heart Valve Society.
Annual Meeting 2018
Information and presentation from the BHVS Annual Meeting held in September 2018.
2 days ago
Full house for #HeadStart2018! Amazing lineup of speakers to tell our first year #cardiology registrars what they wished they new when they first started out #cardioed https://t.co/fcMze8sKiX
Full house for #HeadStart2018! Amazing lineup of speakers to tell our first year #cardiology registrars what they wished they new when they first started out #cardioed https://t.co/fcMze8sKiX
4 days ago
How should we treat low-gradient severe #aorticstenosis? Low baseline gradient & reduced SVi predict higher #TAVR mortality. Low-gradient normal LVEF outcomes similar to high gradient: https://t.co/JB8anrFsmv. #JACCIMG #cardiotwitter #cvVHD https://t.co/Wal63fVoMy
How should we treat low-gradient severe #aorticstenosis? Low baseline gradient & reduced SVi predict higher #TAVR mortality. Low-gradient normal LVEF outcomes similar to high gradient: https://t.co/JB8anrFsmv. #JACCIMG #cardiotwitter #cvVHD https://t.co/Wal63fVoMy
5 days ago
A case report of an unusual cause of mitral stenosis in a young woman https://t.co/6ABoSJ0gug
@escardio @johncamm #EHJCaseReports #ESCCoT #ESCardioEd #CardioTwitter #openaccess https://t.co/tqcnqS6At1
A case report of an unusual cause of mitral stenosis in a young woman https://t.co/6ABoSJ0gug
@escardio @johncamm #EHJCaseReports #ESCCoT #ESCardioEd #CardioTwitter #openaccess https://t.co/tqcnqS6At1
1 week ago
Wow. Amazing day at the @BJCAstarter conference. Well done to all involved. The future of #cardiology is in great hands! #CardioEd https://t.co/9hxWVucGAt
Wow. Amazing day at the @BJCAstarter conference. Well done to all involved. The future of #cardiology is in great hands! #CardioEd https://t.co/9hxWVucGAt
2 weeks ago
521 pts TMVR registry w/ failed MVR [ViV], rings [ViR], MAC [ViMAC]. 2nd valve, >mild MR, PVL closure more in ViR vs ViMAC&ViV. Risk mortality w/ ViR vs.ViV, [HR 1.99,95% CI 1.27–3.12; P=0.003];ViMAC vs.ViV, HR 5.29, 95% CI 3.29–8.51; P<0.001]. https://t.co/fnqQdtj6kP #EchoFirst https://t.co/nkejW2KaCo
521 pts TMVR registry w/ failed MVR [ViV], rings [ViR], MAC [ViMAC]. 2nd valve, >mild MR, PVL closure more in ViR vs ViMAC&ViV. Risk mortality w/ ViR vs.ViV, [HR 1.99,95% CI 1.27–3.12; P=0.003];ViMAC vs.ViV, HR 5.29, 95% CI 3.29–8.51; P<0.001]. https://t.co/fnqQdtj6kP #EchoFirst https://t.co/nkejW2KaCo
3 weeks ago
What is this patient’s heart rhythm? @MasriAhmadMD @malamo512 @msenussiMD @AnumSaeedMD @BPierce_MD @PittCardiology #cardioed #EchoFirst https://t.co/80J7nnT9S0
What is this patient’s heart rhythm? @MasriAhmadMD @malamo512 @msenussiMD @AnumSaeedMD @BPierce_MD @PittCardiology #cardioed #EchoFirst https://t.co/80J7nnT9S0
